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AbsTrACT
we present key points from the updated Dutch- Flemish 
guideline on comprehensive diagnostics in disorders/
differences of sex development (DSD) that have not been 
widely addressed in the current (inter)national literature. 
These points are of interest to physicians working in DSD 
(expert) centres and to professionals who come across 
persons with a DSD but have no (or limited) experience 
in this area. The Dutch- Flemish guideline is based on 
internationally accepted principles. Recent initiatives 
striving for uniform high- quality care across europe, and 
beyond, such as the completed COST action 1303 and 
the european Reference Network for rare endocrine 
conditions (endoeRN), have generated several excellent 
papers covering nearly all aspects of DSD. The Dutch- 
Flemish guideline follows these international consensus 
papers and covers a number of other topics relevant to 
daily practice. For instance, although next- generation 
sequencing (NGS)- based molecular diagnostics are 
becoming the gold standard for genetic evaluation, it 
can be difficult to prove variant causality or relate the 
genotype to the clinical presentation. Network formation 
and centralisation are essential to promote functional 
studies that assess the effects of genetic variants and to 
the correct histological assessment of gonadal material 
from DSD patients, as well as allowing for maximisation 
of expertise and possible cost reductions. The Dutch- 
Flemish guidelines uniquely address three aspects of 
DSD. First, we propose an algorithm for counselling 
and diagnostic evaluation when a DSD is suspected 
prenatally, a clinical situation that is becoming more 
common. Referral to ultrasound sonographers and 
obstetricians who are part of a DSD team is increasingly 
important here. Second, we pay special attention to 
healthcare professionals not working within a DSD 
centre as they are often the first to diagnose or suspect 
a DSD, but are not regularly exposed to DSDs and may 
have limited experience. Their thoughtful communication 
to patients, carers and colleagues, and the accessibility of 
protocols for first- line management and efficient referral 
are essential. Careful communication in the prenatal to 
neonatal period and the adolescent to adult transition 
are equally important and relatively under- reported 
in the literature. Third, we discuss the timing of (NGS- 
based) molecular diagnostics in the initial workup of new 
patients and in people with a diagnosis made solely on 
clinical grounds or those who had earlier genetic testing 
that is not compatible with current state- of- the- art 
diagnostics.
InTroduCTIon
In recent years, many studies have been published 
on new diagnostic possibilities and management 
approaches in cohorts of patients suspected to have 
a disorder/difference of sex development (DSD).1–13 
Based on these studies, it has become clear that 
services and institutions still differ in the composi-
tion of the multidisciplinary teams that provide care 
for patients who have a DSD.11 14 Several projects 
have now worked to resolve this variability in care. 
The European Cooperation in Science and Tech-
nology (EU COST) action BM1303 ‘A systematic 
elucidation of differences of sex development’ has 
been a platform to achieve European agreement on 
harmonisation of clinical management and labora-
tory practices.15–17 Another such initiative involved 
an update of the 2006 DSD consensus document by 
an international group of professionals and patient 
representatives.18 These initiatives have highlighted 
how cultural and financial aspects and the avail-
ability of resources differ significantly between 
countries and societies, a situation that hampers 
supranational agreement on common diagnostic 
protocols. As only a few national guidelines have 
been published in international journals, compar-
ison of these guidelines is difficult even though 
such a comparison is necessary to capture the 
differences and initiate actions to overcome them. 
Nonetheless, four DSD (expert) centres located in 
the Netherlands and Flanders (the Dutch- speaking 
Northern part of Belgium) have collaborated to 
produce a detailed guideline on diagnostics in 
DSD.19 This shows that a supranational guideline 
can be a reasonable approach for countries with 
similarly structured healthcare systems and similar 
resources. Within the guideline there is agreement 
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that optimisation of expertise and care can be achieved through 
centralisation, for example, by limiting analysis of next- 
generation sequencing (NGS)- based diagnostic panels to only a 
few centres and by centralising pathological review of gonadal 
tissues. International networks such as the European Reference 
Network for rare endocrine conditions (EndoERN), in which 
DSD is embedded, may facilitate the expansion of this kind of 
collaboration across Europe.
This paper highlights key discussion points in the Dutch- 
Flemish guideline that have been insufficiently addressed in the 
literature thus far because they reflect evolving technologies or 
less visible stakeholders. For example, prenatal observation of 
an atypical aspect of the genitalia indicating a possible DSD is 
becoming increasingly common, and we discuss appropriate 
counselling and a diagnostic approach for these cases, including 
the option of using NGS- based genetic testing. So far, little atten-
tion has been paid to this process.20 21 Furthermore, informing 
patients and/or their parents about atypical sex development 
and why this may warrant referral to a specialised team may be 
challenging, especially for professionals with limited experience 
in DSD.22 23 Therefore, a section of the Dutch- Flemish guide-
line was written for these healthcare providers. Moreover, this 
enables DSD specialists to refer to the guideline when advising a 
referral. Transition from the prenatal to the postnatal team and 
from the paediatric to the adult team requires optimal commu-
nication between the specialists involved. Application of NGS- 
based techniques may lead to a higher diagnostic yield, providing 
a molecular genetic diagnosis in previously unsolved cases.16 We 
address the timing of this testing and the problems associated 
with this technique such as the interpretation of variants of 
unknown clinical significance (VUS). Similarly, histopatholog-
ical interpretation and classification of removed gonadal tissue is 
challenging and would benefit from international collaboration 
and centralisation of expertise.
MeThods
For the guideline revision, an interdisciplinary multicentre 
group was formed with all members responsible for updating 
the literature for a specific part of the guideline. Literature 
search in PubMed was not systematic, but rather intended to 
be broad in order to cover all areas and follow expert opinions. 
This approach is more in line with the Clinical Practice Advi-
sory Document method described by Burke et al24 for guide-
lines involving genetic practice because it is often troublesome 
to substantiate such guidelines with sufficient evidence due to 
the rapid changes in testing methods, for example, gene panels. 
All input provided by the group was synthesised by the chair-
person (YvB), who also reviewed abstracts of papers on DSD 
published between 2010 and September 2017 for the guide-
line and up to October 2019 for this paper. Abstracts had to be 
written in English and were identified using a broad range of 
Medical Subject Headings terms (eg, DSD, genetic, review, diag-
nosis, diagnostics, 46,XX DSD, 46,XY DSD, guideline, multidis-
ciplinary care). Next, potentially relevant papers on diagnostic 
procedures in DSD were selected. Case reports were excluded, 
as were articles that were not open access or retrievable through 
institutional access. Based on this, a draft guideline was produced 
that was in line with the international principles of good diag-
nostic care in DSD. This draft was discussed by the writing 
committee and, after having obtained agreement on remaining 
points of discussion, revised into a final draft. This version was 
sent to a broad group of professionals from academic centres and 
DSD teams whose members had volunteered to review the draft 
guideline. After receiving and incorporating their input, the final 
version was presented to the paediatric and genetic associations 
for approval. After approval by the members of the paediatric 
(NVK), clinical genetic (VKGN) and genetic laboratory (VKGL) 
associations, the guideline was published on their respective 
websites.19 Although Turner syndrome and Klinefelter syndrome 
are considered to be part of the DSD spectrum, they are not 
extensively discussed in this diagnostic guideline as guidelines 
dedicated to these syndromes already exist.25 26 However, some 
individuals with Turner syndrome or Klinefelter syndrome may 
present with ambiguous or atypical genitalia and may therefore 
initially follow the DSD diagnostic process.
GuIdelIne hIGhlIGhTs
Prenatal setting
Presentation
The most frequent prenatal presentation of a DSD condition is 
atypical genitalia found on prenatal ultrasound as an isolated 
finding or in combination with other structural anomalies. This 
usually occurs after the 20- week routine medical ultrasound for 
screening of congenital anomalies, but may also occur earlier, 
for example, when a commercial ultrasound is performed at the 
request of the parents.
Another way DSD can be diagnosed before birth is when inva-
sive prenatal genetic testing carried out for a different reason, 
for example, due to suspicion of other structural anomalies, 
reveals a discrepancy between the genotypic sex and the pheno-
typic sex seen by ultrasound. In certified laboratories, the possi-
bility of a sample switch is extremely low but should be ruled 
out immediately. More often, the discrepancy will be due to sex- 
chromosome mosaicism or a true form of DSD.
A situation now occurring with increasing frequency is a 
discrepancy between the genotypic sex revealed by non- invasive 
prenatal testing (NIPT), which is now available to high- risk preg-
nant women in the Netherlands and to all pregnant women in 
Belgium, and later ultrasound findings. NIPT screens for CNVs 
in the fetus. However, depending on legal restrictions and/or 
ethical considerations, the X and Y chromosomes are not always 
included in NIPT analysis and reports. If the X and Y chromo-
somes are included, it is important to realise that the presence 
of a Y- chromosome does not necessarily imply male fetal devel-
opment. At the time that NIPT is performed (usually 11–13 
weeks), genital development cannot be reliably appreciated by 
ultrasound, so any discrepancy or atypical aspect of the geni-
talia will only be noticed later in pregnancy and should prompt 
further evaluation.
Counselling and diagnostics
If a DSD is suspected, first- line sonographers and obstetricians 
should refer the couple to their colleague prenatal specialists 
working with or in a DSD team. After confirming an atyp-
ical genital on ultrasound, the specialist team should offer the 
couple a referral for genetic counselling to discuss the possibility 
of performing invasive prenatal testing (usually an amniocen-
tesis) to identify an underlying cause that fits the ultrasound 
findings.22 23 To enable the parents to make a well- informed 
decision, prenatal counselling should, in our opinion, include: 
information on the ultrasound findings and the limitations of 
this technique; the procedure(s) that can be followed, including 
the risks associated with an amniocentesis; and the type of infor-
mation genetic testing can and cannot provide. Knowing which 
information has been provided and what words have been used 
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Figure 1 Disorders/differences of sex development (DSD) in the prenatal 
setting: a diagnostic algorithm. *SOX9: upstream anomalies and balanced 
translocations at promotor sites! Conventional karyotyping can be useful. 
NGS, next- generation sequencing.
by the prenatal specialist is very helpful for those involved in 
postnatal care.
It is important that parents understand that the biological sex 
of a baby is determined by a complex interplay of chromosomes, 
genes and hormones, and thus that assessment of the presence 
or absence of a Y- chromosome alone is insufficient to assign the 
sex of their unborn child or, as in any unborn child, say anything 
about the child’s future gender identity.
Expecting parents can be counselled by the clinical geneticist 
and the psychologist from the DSD team, although other DSD 
specialists can also be involved. The clinical geneticist should 
be experienced in prenatal counselling and well informed about 
the diagnostic possibilities given the limited time span in which 
test results need to be available to allow parents to make a 
well- informed decision about whether or not to continue the 
pregnancy. Termination of pregnancy can be considered, for 
instance, in a syndromic form of DSD with multiple malfor-
mations, but when the DSD occurs as an apparently isolated 
condition, expecting parents may also consider termination of 
pregnancy, which, although considered controversial by some, 
is legal in Belgium and the Netherlands. The psychologist of 
the DSD team can support parents during and after pregnancy 
and help them cope with feelings of uncertainty and eventual 
considerations of a termination of pregnancy, as well as with 
practical issues, for example, how to inform others. The stress 
of not knowing exactly what the child’s genitalia will look 
like and uncertainty about the diagnosis, treatment and prog-
nosis cannot be avoided completely. Parents are informed that 
if the postnatal phenotype is different from what was prena-
tally expected, the advice given about diagnostic testing can be 
adjusted accordingly, for example, if a hypospadias is milder 
than was expected based on prenatal ultrasound images. In our 
experience, parents appreciate having already spoken to some 
members of the DSD team during pregnancy and having a 
contact person before birth.
After expert prenatal counselling, a significant number of 
pregnant couples decline prenatal testing (personal experience 
IALG, MK, ABD, YvB, MC and HC- vdG). At birth, umbilical 
cord blood is a good source for (molecular) karyotyping and 
storage of DNA and can be obtained by the obstetrician, midwife 
or neonatologist. The terminology used in communication with 
parents should be carefully chosen,22 23 and midwives and staff 
of neonatal and delivery units should be clearly instructed to use 
gender- neutral and non- stigmatising vocabulary (eg, ‘your baby’) 
as long as sex assignment is pending.
An algorithm for diagnostic evaluation of a suspected DSD 
in the prenatal situation is proposed in figure 1. When couples 
opt for invasive prenatal diagnosis, the genetic analysis usually 
involves an (SNP)- array. It was recently estimated that >30% of 
individuals who have a DSD have additional structural anoma-
lies, with cardiac and neurological anomalies and fetal growth 
restriction being particularly common.27 28 If additional anom-
alies are seen, the geneticist can consider specific gene defects 
that may underlie a known genetic syndrome or carry out NGS. 
NGS- based techniques have also now made their appearance 
in prenatal diagnosis of congenital anomalies.29 30 Panels using 
these techniques can be specific for genes involved in DSD, or 
be larger panels covering multiple congenital anomalies, and are 
usually employed with trio- analysis to compare variants identi-
fied in the child with the parents’ genetics.29–31 Finding a genetic 
cause before delivery can help reduce parental stress in the 
neonatal period and speed up decisions regarding gender assign-
ment. In such cases there is no tight time limit, and we propose 
completing the analysis well before the expected delivery.
First contact by a professional less experienced in dsd
Whereas most current guidelines start from the point when an 
individual has been referred to the DSD team,1 15 the Dutch- 
Flemish guideline dedicates a chapter to healthcare professionals 
less experienced in DSD as they are often the first to suspect or 
identify such a condition. Apart from the paper of Indyk,7 little 
guidance is available for these professionals about how to act 
in such a situation. The chapter in the Dutch- Flemish guideline 
summarises the various clinical presentations that a DSD can 
have and provides information on how to communicate with 
parents and/or patients about the findings of the physical exam-
ination, the first- line investigations and the need for prompt 
referral to a specialised centre for further evaluation. Clinical 
examples are offered to illustrate some of these recurring situ-
ations. The medical issues in DSD can be very challenging, and 
the social and psychological impact is high. For neonates with 
ambiguous genitalia, sex assignment is an urgent and crucial 
issue, and it is mandatory that parents are informed that it is 
possible to postpone registration of their child’s sex. In cases 
where sex assignment has already taken place, the message that 
the development of the gonads or genitalia is still atypical is 
complicated and distressing for patients and parents or carers. 
A list of contact details for DSD centres and patient organisa-
tions in the Netherlands and Flanders is attached to the Dutch- 
Flemish guideline. Publishing such a list, either in guidelines or 
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Figure 2 46,XX disorders/differences of sex development (DSD) in the postnatal setting: a diagnostic algorithm. NGS, next- generation sequencing. CAH, 
Congenital adrenal hyperplasia; AMH, Anti- Müllerian Hormone.
online, can help healthcare professionals find the nearest centres 
for consultations and provide patients and patient organisations 
with an overview of the centres where expertise is available.
Timing and place of genetic testing using nGs-based gene 
panels
The diagnostic workup that is proposed for 46,XX and 46,XY 
DSD is shown in figures 2 and 3, respectively. Even with the 
rapidly expanding molecular possibilities, a (family) history 
and a physical examination remain the essential first steps in 
the diagnostic process. Biochemical and hormonal screening 
aim at investigating serum electrolytes, renal function and the 
hypothalamic- pituitary- gonadal and hypothalamic- pituitary- 
adrenal axes. Ultrasound screening of kidneys and internal 
genitalia, as well as establishing genotypic sex, should be accom-
plished within 48 hours and complete the baseline diagnostic 
work- up of a child born with ambiguous genitalia.1 16 32 33
Very recently, a European position paper has been published 
focusing on the genetic workup of DSD.16 It highlights the 
limitations and drawbacks of NGS- based tests, which include 
the chance of missing subtle structural variants such as CNVs 
and mosaicism and the fact that NGS cannot detect methyla-
tion defects or other epigenetic changes.16 28 31 Targeted DNA 
analysis is preferred in cases where hormonal investigations 
suggest a block in steroidogenesis (eg, 11-β-hydroxylase defi-
ciency, 21- hydroxylase deficiency), or in the context of a specific 
clinical constellation such as the often coincidental finding of 
Müllerian structures in a boy with normal external genitalia or 
cryptorchidism, that is, persistent Müllerian duct syndrome.33 34 
Alternative tests should also be considered depending on the 
available information. Sometimes, a simple mouth swab for 
FISH analysis can detect mosaic XY/X in a male with hypospa-
dias or asymmetric gonadal development or in a female with 
little or no Turner syndrome stigmata and a normal male molec-
ular karyotyping profile or peripheral blood karyotype. Such 
targeted testing avoids incidental findings and is cheaper and 
faster than analysis of a large NGS- based panel, although the 
cost difference is rapidly declining.
However, due to the genetic and phenotypic heterogeneity 
of DSD conditions, the most cost- effective next steps in the 
majority of cases are whole exome sequencing followed by 
panel analysis of genes involved in genital development and 
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Figure 3 46,XY disorders/differences of sex development (DSD) in the postnatal setting: a diagnostic algorithm. *SOX9: upstream anomalies and balanced 
translocations at promotor sites! Conventional karyotyping can be useful. NGS, next- generation sequencing.
function or trio- analysis of a large gene panel (such as a Mende-
liome).16 35–38 Pretest genetic counselling involves discussing 
what kind of information will be reported to patients or parents 
and the chance of detecting VUS, and the small risk of incidental 
findings when analysing a DSD panel should be mentioned. 
Laboratories also differ in what class of variants they report.39 In 
our experience, the fear of incidental findings is a major reason 
why some parents refrain from genetic testing.
Timing of the DSD gene panel analysis is also important. While 
some patients or parents prefer that all diagnostic procedures 
be performed as soon as possible, others need time to reflect 
on the complex information related to more extensive genetic 
testing and on its possible consequences. If parents or patients 
do not consent to panel- based genetic testing, analysis of specific 
genes, such as WT1, should be considered when appropriate in 
view of the clinical consequences if a mutation is present (eg, 
clinical surveillance of renal function and screening for Wilms’ 
tumour in the case of WT1 mutations). Genes that are more 
frequently involved in DSD (eg, SRY, NR5A1) and that match 
the specific clinical and hormonal features in a given patient 
could also be considered for sequencing. Targeted gene analysis 
may also be preferred in centres located in countries that do not 
have the resources or technical requirements to perform NGS 
panel- based genetic testing. Alternatively, participation by these 
centres in international collaborative networks may allow them 
to outsource the molecular genetic workup abroad.
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Gene panels differ between centres and are regularly updated 
based on scientific progress. A comparison of DSD gene panels 
used in recent studies can be found at https://www. nature. com/ 
articles/ s41574- 018- 0010- 8# Sec46.15 The panels currently used 
at the coauthors’ institutions can be found on their respective 
websites. Given the pace of change, it is important to regularly 
consider repeating analysis in patients with an unexplained DSD, 
for example, when they transition into adult care or when they 
move from one centre to another. This also applies to patients in 
whom a clinical diagnosis has never been genetically confirmed. 
Confusion may arise when the diagnosis cannot be confirmed or 
when a mutation is identified in a different gene, for example, 
NR5A1 in someone with a clinical diagnosis of CAIS that has 
other consequences for relatives. Hence, new genetic counselling 
should always accompany new diagnostic endeavours.
Class 3 variants and histopathological examinations
The rapidly evolving diagnostic possibilities raise new ques-
tions: What do laboratories report? How should we deal with 
the frequent findings of mainly unique VUS or class 3 variants 
(ACMG recommendation) in the many different DSD- related 
genes in the diagnostic setting? Reporting VUS can be a source 
of uncertainty for parents, but not reporting these variants 
precludes further investigations to determine their possible 
pathogenicity. It can also be difficult to prove variant pathoge-
nicity, both on gene- level and variant- level.39 Moreover, given 
the gonad- specific expression of some genes and the variable 
phenotypic spectrum and reduced penetrance, segregation anal-
ysis is not always informative. A class 3 variant that does not 
fit the clinical presentation may be unrelated to the observed 
phenotype, but it could also represent a newly emerging pheno-
type. This was recently demonstrated by the identification of 
the NR5A1 mutation, R92W, in individuals with 46,XX testic-
ular and ovotesticular DSD.40 This gene had previously been 
associated with 46,XY DSD. In diagnostic laboratories, there is 
usually no capacity or expertise to conduct large- scale functional 
studies to determine pathogenicity of these unique class 3 VUS 
in the different genes involved in DSD. Functional validation of 
variants identified in novel genes may be more attractive in a 
research context. However, for individual families with VUS in 
well- established DSD genes such as AR or HSD17B3, functional 
analysis may provide a confirmed diagnosis that implies for rela-
tives the option of undergoing their own DNA analysis and esti-
mating the genetic risk of their own future offspring. This makes 
genetic follow- up important in these cases and demonstrates 
the usefulness of international databases and networks and the 
centralisation of functional studies of genetic variants in order to 
reduce costs and maximise expertise.
The same is true for histopathological description, germ- cell 
tumour risk assessment in specific forms of DSD and classifica-
tion of gonadal samples. Germ- cell tumour risk is related to the 
type of DSD (among other factors), but it is impossible to make 
risk estimates in individual cases.41–44 Gonadectomy may be indi-
cated in cases with high- risk dysgenetic abdominal gonads that 
cannot be brought into a stable superficial (ie, inguinal, labio-
scrotal) position that allows clinical or radiological surveillance, 
or to avoid virilisation due to 5- alpha reductase deficiency in 
a 46,XY girl with a stable female gender identity.45 Patholog-
ical examination of DSD gonads requires specific expertise. For 
example, the differentiation between benign germ cell abnor-
malities, such as delayed maturation and (pre)malignant devel-
opment of germ cells, is crucial for clinical management but can 
be very troublesome.46 Centralised pathological examination 
of gonadal biopsy and gonadectomy samples in one centre, or 
a restricted number of centres, on a national scale can help to 
overcome the problem of non- uniform classification and has 
proven feasible in the Netherlands and Belgium. We therefore 
believe that uniform assessment and classification of gonadal 
differentiation patterns should also be addressed in guidelines 
on DSD management.
International databases of gonadal tissues are crucial for 
learning more about the risk of malignancy in different forms of 
DSD, but they are only reliable if uniform criteria for histological 
classification are strictly applied.46 These criteria could be incor-
porated in many existing networks such as the I- DSD consor-
tium, the Disorders of Sex Development Translational Research 
Network, the European Reference Network on Urogenital 
Diseases (eUROGEN), the EndoERN and COST actions.15–17 47
Communication at the transition from paediatric to adult care
Paediatric and adult teams need to collaborate closely to facili-
tate a well- organised transition from paediatric to adult specialist 
care.15 48–50 Both teams need to exchange information optimally 
and should consider transition as a longitudinal process rather 
than a fixed moment in time. Age- appropriate information is key 
at all ages, and an overview of topics to be discussed at each stage 
is described by Cools et al.15 Table 1 shows an example of how 
transition can be organised.
Psychological support and the continued provision of infor-
mation remains important for individuals with a DSD at all 
ages.15 22 In addition to the information given by the DSD team 
members, families and patients can benefit from resources such 
as support groups and information available on the internet.47 
Information available online should be checked for accuracy and 
completeness when referring patients and parents to internet 
sites.
reCoMMendATIons For FuTure ACTIons
Most guidelines and articles on the diagnosis and manage-
ment of DSD are aimed at specialists and are only published in 
specialist journals or on websites for endocrinologists, urologists 
or geneticists. Yet there is a need for guidelines directed towards 
first- line and second- line healthcare workers that summarise the 
recommendations about the first crucial steps in the manage-
ment of DSD. These should be published in widely available 
general medical journals and online, along with a national list 
of DSD centres. Furthermore, DSD (expert) centres should 
provide continuous education to all those who may be involved 
in the identification of individuals with a DSD in order to enable 
these healthcare professionals to recognise atypical genitalia, 
to promptly refer individuals who have a DSD and to inform 
the patient and parents about this and subsequent diagnostic 
procedures.
As DSD continues to be a rare condition, it will take time to 
evaluate the effects of having such a guideline on the prepared-
ness of first- line and second- line healthcare workers to recognise 
DSD conditions. One way to evaluate this might be the devel-
opment and use of questionnaires asking patients, carers and 
families and referring physicians how satisfied they were with 
the initial medical consultation and referral and what could be 
improved. A helpful addition to existing international data-
bases that collect information on genetic variations would be a 
list of centres that offer suitable functional studies for certain 
genes, ideally covering the most frequently mutated genes (at 
minimum).
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Table 1 Example of transition table as used in the DSD clinic of the Erasmus Medical Center
Age (years) endocrine, urologic, genetic, psychosocial care multidisciplinary team
<11  ► Diagnostics, follow- up, treatment as indicated for the specific DSD.
 ► Provide information about the condition to parents and children, including information about the expected pubertal changes.
 ► Obtain informed consent whenever needed from parents as well as informed assent from children, in compliance with the Dutch and Belgian Law.
 ► Support children and parents to promote coping.
 ► Inform the children about their condition, taking into account their developmental phase.
 ► Observe the children’s developing gender identity and facilitate open discussion if needed.
11–12  ► Evaluate puberty. Hormonal testing and treatment if needed. Provide information.
 ► Imaging studies as necessary. If applicable, in case of a girl discuss future gonadal surgeries or vaginal dilatation depending on sexual development. Provide 
information on pros and cons.
 ► Evaluate if genetic tests should be expanded and if parents and children are open to this.
 ► Provide the children with additional and more detailed information on diagnosis and consequences for pubertal development.
 ► Establish if parents/carers need help with informing the children.
11–17 Multidisciplinary team: preparation for adolescence and adulthood.
 ► Responsibility shifting from parents to patients (eg, knowledge about diagnosis and practical management of medication, independent doctor visits, where to 
find information, what help is available).
 ► Check that adolescents are fully informed about diagnosis, management, follow- up and both necessary and optional diagnostic and therapeutic procedures. 
Sexual development, romantic relationships, sex education, optimal procedures to facilitate sexual intercourse like vaginal dilation and fertility (options) need 
to be addressed.
 ► This age period may not be the best time to perform broad genetic analysis as adolescents are often not yet be able to process the consequences of uncertain 
or incidental findings. However, if genetic testing is performed, consent should be obtained from the adolescents as well.
17–18  ► Transfer of care with adult and paediatric specialists in a joint multidisciplinary meeting and/or outpatient clinical setting.
Ages are approximate, and cognitive, physical and socioemotional development should be taken into account. The process of informing children about their condition and 
making them more and more responsible for the management is gradual.
DSD, disorders/differences of sex development.
Patient organisations can also play an important role in 
informing patients about newly available diagnostic or thera-
peutic strategies and options, and their influence and specific 
role has now been recognised and discussed in several publica-
tions.17 47 However, it should be kept in mind that these organ-
isations do not represent all patients, as a substantial number of 
patients and parents are not member of such an organisation.
Professionals have to provide optimal medical care based on 
well- established evidence, or at least on broad consensus. Yet not 
everything can be regulated by recommendations and guidelines. 
Options, ideas and wishes should be openly discussed between 
professionals, patients and families within their confidential 
relationship. This will enable highly individualised holistic care 
tailored to the patient’s needs and expectations. Once they are 
well- informed of all available options, parents and/or patients 
can choose what they consider the optimal care for their chil-
dren or themselves.15 16
ConClusIon
The Dutch- Flemish guideline uniquely addresses some topics 
that are under- represented in the literature, thus adding some 
key aspects to those addressed in recent consensus papers and 
guidelines.15–17 33 47
As more children with a DSD are now being identified prena-
tally, and the literature on prenatal diagnosis of DSD remains 
scarce,20 21 we propose a prenatal diagnostic algorithm and 
emphasise the importance of having a prenatal specialist involved 
in or collaborating with DSD (expert) centres.
We also stress that good communication between all involved 
parties is essential. Professionals should be well informed about 
protocols and communication. Collaboration between centres 
is necessary to optimise aspects of care such as uniform inter-
pretation of gonadal pathology and functional testing of class 
3 variants found by genetic testing. Guidelines can provide a 
framework within which individualised patient care should be 
discussed with all stakeholders.
Author affiliations
1Department of Clinical Genetics and DSD expert Center erasmus Medical Center, 
erasmus Medical Center, Rotterdam, The Netherlands
2Department of Pediatric Urology and DSD expert Center erasmus Medical Center, 
erasmus Medical Center, Rotterdam, The Netherlands
3Department of Child and Adolescent Psychiatry and DSD expert Center erasmus 
Medical Center, erasmus Medical Center, Rotterdam, The Netherlands
4Department of Obstetrics and Prenatal Medicine and DSD expert Center erasmus 
Medical Center, erasmus Medical Centre, Rotterdam, The Netherlands
5Center for Medical Genetics, University Hospital Ghent Center Medical Genetics, 
Ghent, Belgium
6Department of internal Medicine and Paediatrics and Department of Pediatric 
endocrinology, University Hospital Ghent, Ghent, Belgium
7Department of Genetics and DSD team, University Medical Center Groningen, 
Groningen, The Netherlands
8Department of Pediatric endocrinology and DSD expert Center Radboud UMC, 
Radboud University Medical Center, Amalia Children’s Hospital, Nijmegen, The 
Netherlands
9Department of Clinical genetics and DSD expert Center Radboud UMC, Radboud 
University Medical Center, Nijmegen, The Netherlands
10Department of Pathology, DSD expert Center erasmusMC, erasmus MC- University 
Medical Centre, Rotterdam, The Netherlands
11Department of Pathology, Princess Máxima Center for Pediatric Oncology, Utrecht, 
The Netherlands
12Department of Pediatric endocrinology and DSD expert Center erasmusMC, 
erasmus Medical Center, 3015 GD Rotterdam, The Netherlands
13Department of Pediatrics, Leiden University Medical Center, Leiden, Zuid- Holland, 
The Netherlands
Twitter elfride De Baere @elfridedebaere
Acknowledgements The authors would like to thank the colleagues of the 
DSD teams for their input in and critical reading of the Dutch- Flemish guideline: 
Amsterdam University Center (AMC and vU), Maastricht University Medical Center, 
erasmus Medical Center Rotterdam, Radboud University Medical Center Nijmegen, 
University Medical Center Groningen, University Medical Center Utrecht, Ghent 
University Hospital. The authors would like to thank Kate Mcintyre for editing the 
revised manuscript and Tom de vries Lentsch for providing the figures as a PDF. Three 
of the authors of this publication are members of the european Reference Network 
for rare endocrine diseases—Project iD 739543.
Contributors Design, conceptualisation, submission and overall responsibility: 
YvB. Clinical and psychosocial information collection : YvB, KPw, ABD, MC, CvR- A, 
HC- vdG, MK, SeH. Genetic information collection: YvB, HTB, eDB, CvR- A, MK, TR. 
Prenatal information collection: YvB, ABD, iALG, MFCMK, MC, HC- vdG. Pathological 
 o
n
 M
ay 5, 2020 by guest. Protected by copyright.
http://jmg.bmj.com/
J M
ed G
enet: first published as 10.1136/jmedgenet-2019-106354 on 17 April 2020. Downloaded from 
8 Bever Y, et al. J Med Genet 2020;0:1–9. doi:10.1136/jmedgenet-2019-106354
Clinical guidelines
aspects: MC, RH, LL. writing the manuscript: YvB, HTB, eDB, MC, HC- vdG, SeH. 
Critical review: HTB, KPw, ABD, iALG, MFCMK, eDB, MC, CvR- A, HC- vdG, MK, LL, 
MC.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
orCId id
Yolande van Bever http:// orcid. org/ 0000- 0003- 2002- 9145
reFerenCes
 1 Ahmed SF, Achermann JC, Arlt w, Balen A, Conway G, edwards Z, elford S, Hughes 
iA, izatt L, Krone N, Miles H, O’Toole S, Perry L, Sanders C, Simmonds M, watt A, 
willis D. Society for endocrinology UK guidance on the initial evaluation of an infant 
or an adolescent with a suspected disorder of sex development (revised 2015). Clin 
Endocrinol 2016;84:771–88.
 2 Douglas G, Axelrad Me, Brandt ML, Crabtree e, Dietrich Je, French S, Gunn S, Karaviti 
L, Lopez Me, Macias CG, McCullough LB, Suresh D, Austin e, Reid Sutton v, Sutton 
R v. Guidelines for evaluating and managing children born with disorders of sexual 
development. Pediatr Ann 2012;41:e81–6.
 3 wisniewski AB, Batista RL, Costa eMF, Finlayson C, Sircili MHP, Dénes FT, Domenice 
S, Mendonca BB. Management of 46,XY Differences/Disorders of Sex Development 
(DSD) Throughout Life. Endocr Rev 2019;40:1547–72.
 4 Krege S, eckoldt F, Richter- Unruh A, Köhler B, Leuschner i, Mentzel H- J, Moss A, 
Schweizer K, Stein R, werner- Rosen K, wieacker P, wiesemann C, wünsch L, Richter- 
Appelt H. variations of sex development: the first German interdisciplinary consensus 
paper. J Pediatr Urol 2019;15:114–23.
 5 Baetens D, Mladenov w, Delle Chiaie B, Menten B, Desloovere A, iotova v, Callewaert 
B, van Laecke e, Hoebeke P, De Baere e, Cools M. extensive clinical, hormonal and 
genetic screening in a large consecutive series of 46,XY neonates and infants with 
atypical sexual development. Orphanet J Rare Dis 2014;9:209.
 6 Brain Ce, Creighton SM, Mushtaq i, Carmichael PA, Barnicoat A, Honour Jw, Larcher 
v, Achermann JC. Holistic management of DSD. Best Pract Res Clin Endocrinol Metab 
2010;24:335–54.
 7 indyk JA. Disorders/differences of sex development (DSDs) for primary care: the 
approach to the infant with ambiguous genitalia. Transl Pediatr 2017;6:323–34.
 8 Khadilkar vv, Phanse- Gupte S. issues in the diagnosis and management of disorders 
of sexual development. Indian J Pediatr 2014;81:66–75.
 9 Bangalore Krishna K, Houk CP, Lee PA. Pragmatic approach to intersex, including 
genital ambiguity, in the newborn. Semin Perinatol 2017;41:244–51.
 10 Romao RLP, Pippi Salle JL, wherrett DK. Update on the management of disorders of 
sex development. Pediatr Clin North Am 2012;59:853–69.
 11 Kyriakou A, Dessens A, Bryce J, iotova v, Juul A, Krawczynski M, Nordenskjöld A, 
Rozas M, Sanders C, Hiort O, Ahmed SF. Current models of care for disorders of sex 
development – results from an international survey of specialist centres. Orphanet J 
Rare Dis 2016;11:155.
 12 Houk CP, Lee PA. Update on disorders of sex development. Curr Opin Endocrinol 
Diabetes Obes 2012;19:28–32.
 13 Palmer Bw, wisniewski AB, Schaeffer TL, Mallappa A, Tryggestad JB, Krishnan S, 
Chalmers LJ, Copeland K, Chernausek SD, Reiner wG, Kropp BP. A model of delivering 
multi- disciplinary care to people with 46 XY DSD. J Pediatr Urol 2012;8:7–16.
 14 Rolston AM, Gardner M, van Leeuwen K, Mohnach L, Keegan C, Délot e, vilain 
e, Sandberg De. Members of the DSD- TRN advocacy; Advisory network ACCORD 
alliance. disorders of sex development (DSD): clinical service delivery in the United 
States. Am J Med Genet C Semin Med Genet 2017;175:268–78.
 15 Cools M, Nordenström A, Robeva R, Hall J, westerveld P, Flück KB, Berra M, Springer 
A, Schweizer K, Pasterski v. Cost action BM1303 working group 1. caring for 
individuals with a difference of sex development (DSD): a consensus statement. Nat 
rev 2018;14:415–29.
 16 Audí L, Ahmed SF, Krone N, Cools M, Mcelreavey K, Holterhus PM, Greenfield A, 
Bashamboo A, Hiort O, wudy SA, McGowan R, The eU COST Action. GeNeTiCS iN 
eNDOCRiNOLOGY: Approaches to molecular genetic diagnosis in the management of 
differences/disorders of sex development (DSD): position paper of eU COST Action BM 
1303 ’DSDnet’. Eur J Endocrinol 2018;179:R197–206.
 17 Flück C, Nordenström A, Ahmed SF, Ali SR, Berra M, Hall J, Köhler B, Pasterski v, 
Robeva R, Schweizer K, Springer A, westerveld P, Hiort O, Cools M. Standardised data 
collection for clinical follow- up and assessment of outcomes in differences of sex 
development (DSD): recommendations from the cost action DSDnet. Eur J Endocrinol 
2019;181:545–64.
 18 Lee PA, Nordenström A, Houk CP, Ahmed SF, Auchus R, Baratz A, Baratz Dalke K, 
Liao L- M, Lin- Su K, Looijenga 3rd LHJ, Mazur T, Meyer- Bahlburg HFL, Mouriquand P, 
Quigley CA, Sandberg De, vilain e, witchel S, and the Global DSD Update Consortium. 
Global disorders of sex development update since 2006: perceptions, approach and 
care. Horm Res Paediatr 2016;85:158–80.
 19 van Bever Y, Brüggenwirth H, Dessens AB, Hannema Se, wolffenbuttel KP, DeBaere 
e, Cools M, Haadsma M, van Ravenswaaij- Arts C, Sikkema- Radatz B, Claahsen- 
van der Grinten H, Kempers M, Rinne T. Multidisciplinaire richtlijn: Diagnostiek 
bij disorders/differences of sex development (DSD), 2017. Available: http://www. 
vkgn. org>vakinformatie>richtlijnen en protocollen>overig; https://www. nvk. 
nl>kwaliteit>richtlijnen overzicht>lijst
 20 Adam MP, Fechner PY, Ramsdell LA, Badaru A, Grady Re, Pagon RA, McCauley e, 
Cheng eY, Parisi MA, Shnorhavorian M. Ambiguous genitalia: what prenatal genetic 
testing is practical? Am J Med Genet A 2012;158A:1337–43.
 21 Chitty LS, Chatelain P, wolffenbuttel KP, Aigrain Y. Prenatal management of disorders 
of sex development. J Pediatr Urol 2012;8:576–84.
 22 Dessens A, Guaragna- Filho G, Kyriakou A, Bryce J, Sanders C, Nordenskjöld A, Rozas 
M, iotova v, ediati A, Juul A, Krawczynski M, Hiort O, Faisal Ahmed S. Understanding 
the needs of professionals who provide psychosocial care for children and adults with 
disorders of sex development. BMJ Paediatr Open 2017;1. erratum in: BMJ Paediatr 
Open. 2018 Feb 23;2(1).
 23 wilson JD, Rivarola MA, Mendonca BB, warne GL, Josso N, Drop SLS, Grumbach MM. 
Advice on the management of ambiguous genitalia to a young endocrinologist from 
experienced clinicians. Semin Reprod Med 2012;30:339–50.
 24 Burke w, Clayton ew, wolf SM, Berry SA, evans BJ, evans JP, Hall R, Korngiebel D, 
Laberge A- M, LeRoy BS, McGuire AL. improving recommendations for genomic 
medicine: building an evolutionary process from clinical practice Advisory documents 
to guidelines. Genet Med 2019;21:2431–8.
 25 Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner Me, Klein KO, Lin Ae, 
Mauras N, Quigley CA, Rubin K, Sandberg De, Sas TCJ, Silberbach M, Söderström- 
Anttila v, Stochholm K, van Alfen- van dervelden JA, woelfle J, Backeljauw PF, 
international Turner Syndrome Consensus Group. Clinical practice guidelines for the 
care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati 
international Turner syndrome meeting. Eur J Endocrinol 2017;177:G1–70.
 26 De Ronde P, Swaab H, Giltay J, van wieringen H. Leidraad Syndroom van Klinefelter, 
2016. Available: https://www. nve
 27 Alimussina M, Diver LA, McGowan R, Ahmed SF. Genetic testing of XY newborns with 
a suspected disorder of sex development. Curr Opin Pediatr 2018;30:548–57.
 28 Al- Juraibah FN, Lucas- Herald AK, Alimussina M, Ahmed SF. The evaluation 
and management of the boy with DSD. Best Pract Res Clin Endocrinol Metab 
2018;32:445–53.
 29 Best S, wou K, vora N, van der veyver iB, wapner R, Chitty LS. Promises, pitfalls and 
practicalities of prenatal whole exome sequencing. Prenat Diagn 2018;38:10–19.
 30 Leung GKC, Mak CCY, Fung JLF, wong wHS, Tsang MHY, Yu MHC, Pei SLC, Yeung KS, 
Mok GTK, Lee CP, Hui APw, Tang MHY, Chan KYK, Liu APY, Yang w, Sham PC, Kan 
ASY, Chung BHY, MHC Y, SLC P, GTK M, APw H, APY L, ASY K. identifying the genetic 
causes for prenatally diagnosed structural congenital anomalies (SCAs) by whole- 
exome sequencing (weS). BMC Med Genomics 2018;11:93.
 31 Amarillo ie, Nievera i, Hagan A, Huchthagowder v, Heeley J, Hollander A, Koenig J, 
Austin P, wang T. integrated small copy number variations and epigenome maps of 
disorders of sex development. Hum Genome Var 2016;3.
 32 Hannema Se, de Rijke YB. improving laboratory assessment in disorders of sex 
development through a multidisciplinary network. Sex Dev 2018;12:135–9.
 33 Kulle A, Krone N, Holterhus PM, Schuler G, Greaves RF, Juul A, de Rijke YB, Hartmann 
MF, Saba A, Hiort O, wudy SA, COST Action eU, eU COST Action. Steroid hormone 
analysis in diagnosis and treatment of DSD: position paper of eU COST Action BM 
1303 ’DSDnet’. Eur J Endocrinol 2017;176:P1–9.
 34 van der Zwan YG, Brüggenwirth HT, Drop SLS, wolffenbuttel KP, Madern GC, 
Looijenga LHJ, visser JA. A novel AMH missense mutation in a patient with persistent 
Müllerian duct syndrome. Sex Dev 2012;6:279–83.
 35 Arboleda vA, Lee H, Sánchez FJ, Délot eC, Sandberg De, Grody ww, Nelson SF, vilain 
e. Targeted massively parallel sequencing provides comprehensive genetic diagnosis 
for patients with disorders of sex development. Clin Genet 2013;83:35–43.
 36 Baxter RM, Arboleda vA, Lee H, Barseghyan H, Adam MP, Fechner PY, Bargman R, 
Keegan C, Travers S, Schelley S, Hudgins L, Mathew RP, Stalker HJ, Zori R, Gordon OK, 
Ramos- Platt L, Pawlikowska- Haddal A, eskin A, Nelson SF, Délot e, vilain e. exome 
sequencing for the diagnosis of 46,XY disorders of sex development. The Clin of 
Metab 2015;100:e333–44.
 37 Dong Y, Yi Y, Yao H, Yang Z, Hu H, Liu J, Gao C, Zhang M, Zhou L, Yi X, Liang Z. 
Targeted next- generation sequencing identification of mutations in patients with 
disorders of sex development. BMC Med Genet 2016;17:23.
 38 eggers S, Sadedin S, van den Bergen JA, Robevska G, Ohnesorg T, Hewitt J, Lambeth 
L, Bouty A, Knarston iM, Tan TY, Cameron F, werther G, Hutson J, O’Connell M, 
Grover SR, Heloury Y, Zacharin M, Bergman P, Kimber C, Brown J, webb N, Hunter 
MF, Srinivasan S, Titmuss A, verge CF, Mowat D, Smith G, Smith J, ewans L, Shalhoub 
C, Crock P, Cowell C, Leong GM, Ono M, Lafferty AR, Huynh T, visser U, Choong CS, 
 o
n
 M
ay 5, 2020 by guest. Protected by copyright.
http://jmg.bmj.com/
J M
ed G
enet: first published as 10.1136/jmedgenet-2019-106354 on 17 April 2020. Downloaded from 
9Bever Y, et al. J Med Genet 2020;0:1–9. doi:10.1136/jmedgenet-2019-106354
Clinical guidelines
McKenzie F, Pachter N, Thompson eM, Couper J, Baxendale A, Gecz J, wheeler BJ, 
Jefferies C, MacKenzie K, Hofman P, Carter P, King Ri, Krausz C, van Ravenswaaij- 
Arts CM, Looijenga L, Drop S, Riedl S, Cools M, Dawson A, Juniarto AZ, Khadilkar v, 
Khadilkar A, Bhatia v, Dũng vC, Atta i, Raza J. Disorders of sex development: insights 
from targeted gene sequencing of a large international patient cohort. Genome Biol. 
2016 Nov;17(1):243 development patients. Endocr Dev;2014:185–96.
 39 MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, Adams 
DR, Altman RB, Antonarakis Se, Ashley eA, Barrett JC, Biesecker LG, Conrad DF, 
Cooper GM, Cox NJ, Daly MJ, Gerstein MB, Goldstein DB, Hirschhorn JN, Leal SM, 
Pennacchio LA, Stamatoyannopoulos JA, Sunyaev SR, valle D, voight BF, winckler 
w, Gunter C. Guidelines for investigating causality of sequence variants in human 
disease. Nature 2014;508:469–76.
 40 Baetens D, Stoop H, Peelman F, Todeschini A- L, Rosseel T, Coppieters F, veitia 
RA, Looijenga LHJ, De Baere e, Cools M. NR5A1 is a novel disease gene for 
46,XX testicular and ovotesticular disorders of sex development. Genet Med 
2017;19:367–76.
 41 wolffenbuttel KP, Hersmus R, Stoop H, Biermann K, Hoebeke P, Cools M, Looijenga 
LHJ. Gonadal dysgenesis in disorders of sex development: diagnosis and surgical 
management. J Pediatr Urol 2016;12:411–6.
 42 Duzkale H, Shen J, McLaughlin H, Alfares A, Kelly MA, Pugh TJ, Funke BH, Rehm HL, 
Lebo MS. A systematic approach to assessing the clinical significance of genetic 
variants. Clin Genet 2013;84:453–63.
 43 Cools M, Looijenga LHJ, wolffenbuttel KP, T’Sjoen G. Managing the risk of 
germ cell tumourigenesis in disorders of sex development patients. Endocr Dev 
2014;27:185–96.
 44 van der Zwan YG, Biermann K, wolffenbuttel KP, Cools M, Looijenga LHJ. Gonadal 
maldevelopment as risk factor for germ cell cancer: towards a clinical decision model. 
Eur Urol 2015;67:692–701.
 45 Abacı A, Çatlı G, Kırbıyık Ö., Şahin NM, Abalı ZY, Ünal e, Şıklar Z, Mengen e, Özen 
S, Güran T, Kara C, Yıldız M, eren e, Nalbantoğlu Ö., Güven A, Çayır A, Akbaş eD, 
Kor Y, Çürek Y, Aycan Z, Baş F, Darcan Ş., Berberoğlu M, Ö K, Ö N, Ş D. Genotype–
phenotype correlation, gonadal malignancy risk, gender preference, and testosterone/
dihydrotestosterone ratio in steroid 5- alpha- reductase type 2 deficiency: a multicenter 
study from turkey. J Endocrinol Invest 2019;42:453–70.
 46 Spoor JA, Oosterhuis Jw, Hersmus R, Biermann K, wolffenbuttel KP, Cools M, Kazmi 
Z, Ahmed SF, Looijenga LHJ. Histological assessment of gonads in DSD: relevance for 
clinical management. Sex Dev 2018;12:106–22.
 47 Sanders C, Hall J, Sanders C, Dessens A, Bryce J, Callens N, Cools M, Kourime M, 
Kyriakou A, Springer A, Audi L, Balsamo A, iotova v, Mladenov v, Krawczynski M, 
Nordenskjöld A, Rozas M, Claahsen- van der Grinten H, Hiort O, Riedl S, Ahmed SF. 
involving individuals with disorders of sex development and their parents in exploring 
new models of shared learning: proceedings from a DSDnet cost action workshop. Sex 
Dev 2018;12:225–31.
 48 Amies Oelschlager AM, Muscarella M, Gomez- Lobo v. Transition to adult care in 
persons with disorders of sexual development: the role of the gynecologist. Obstet 
Gynecol 2015;126:845–9.
 49 Crouch NS, Creighton SM. Transition of care for adolescents with disorders of sex 
development. Nat Rev Endocrinol 2014;10:436–42.
 50 Auchus R, Quint e. Adolescents with disorders of sex development (DSD) – lost in 
transition? Horm Metab Res 2015;47:367–74.
 o
n
 M
ay 5, 2020 by guest. Protected by copyright.
http://jmg.bmj.com/
J M
ed G
enet: first published as 10.1136/jmedgenet-2019-106354 on 17 April 2020. Downloaded from 
